Drug Profile


Alternative Names: Cetrorelix acetate; Cetrorelix pamoate; Cetrotide; NS 75A; NS 75B; SB 075; SB 75

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tulane University
  • Developer AEterna Zentaris Inc; Merck Serono; Shionogi
  • Class Infertility therapies; Peptides
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility
  • Discontinued Benign prostatic hyperplasia; Breast cancer; Endometriosis; Ovarian cancer; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 01 Oct 2013 AEterna Zentaris completes transfer of worldwide manufacturing rights to cetrorelix to Merck KGaA (Merck Serono)
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
  • 23 Apr 2013 AEterna Zentaris announces its decision to transfer manufacturing rights to cetrorelix to Merck KGaA (Merck Serono)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top